Eugène Cox

Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial

Faustino Torrico, Joaquím Gascón, Lourdes Ortiz et al. · The Lancet Infectious Diseases · 2018 · 297 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +6

JNJ-26481585, a Novel Second-Generation Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity

Janine Arts, Peter King, Ann Marin et al. · Clinical Cancer Research · 2009 · 232 citations

Medicine, Oncology, Pharmacology +12

Population pharmacokinetics and exposure‐response of osimertinib in patients with non‐small cell lung cancer

Kathryn H. Brown, Craig Comisar, Han Witjes et al. · British Journal of Clinical Pharmacology · 2016 · 147 citations · Full text

Medicine, Oncology, Pharmacology +13

Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection

Florence Namour, Paul M. Diderichsen, Eugène Cox et al. · Clinical Pharmacokinetics · 2015 · 136 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Pharmacokinetic-Pharmacodynamic Modeling of the Electroencephalogram Effect of Synthetic Opioids in the Rat: Correlation with the Interaction at the Mu-Opioid Receptor

Eugène Cox, Thomas Kerbusch, Piet H. van der Graaf et al. · Journal of Pharmacology and Experimental Therapeutics · 1998 · 74 citations

Medicine, Pharmacokinetics, Pharmacology +15